BG Medicine outlines $80M IPO to fund expansion

BG Medicine, which is in the business of biomarker discovery and diagnostic testing, has filed for an $80 million IPO. BG, which lost $1.5 million in the quarter ended March 31, says it will use the money for discovery and development activities. That includes "expanding and enhancing laboratory infrastructure and acquiring clinical samples, licensing or acquiring additional product candidates or technologies, and establishing infrastructure to commercialize product candidates."

- see BG's release on the IPO
- read the AP report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.